Kooperativer Bibliotheksverbund

In: Bauphysik, Wiley, Vol. 43, No. 4 ( 2021-08), p. 222-230

Abstract: Fire performance of insulating materials made from renewable resources – Part 1: Experimental investigations of smouldering processes and emissions In the research project ”more than just insulation – additional benefits of insulating materials made from renewable resources“, several sub‐projects investigated the moisture protection, thermal protection, noise insulation and fire protection as well as the sustainability and emission effect of insulating materials made from renewable resources. The primary goal of the research network was to significantly increase the applicability of renewable insulating materials and to eliminate obstacles to their use. In the field of fire protection behavior, the smoldering and burning of renewable insulation materials was analyzed and application limits defined in the context of multi‐storey buildings. The presented article deals with the experimental investigations on initiation, process and extinguishing behavior of smoldering, the effect of flame retardants and the emissions released in the combustion process. In the following article, the structural use of renewable insulation materials, instead of the previously required non‐combustible insulation, is presented in the context of wood panel construction.

Type of Medium: Online Resource

ISSN: 0171-5445 , 1437-0980

URL: Issue

URL: Article

DOI: 10.1002/bapi.v43.4

DOI: 10.1002/bapi.202100018

Language: German

Publisher: Wiley

Publication Date: 2021

detail.hit.zdb_id: 2151235-8

detail.hit.zdb_id: 244802-6

In: Fire and Materials, Wiley, Vol. 47, No. 1 ( 2023-01), p. 3-15

Abstract: Obviously, the use of insulation materials from renewable resources in buildings could provide benefits regarding environmental protection and sustainable management. Nevertheless, their market share in Germany is estimated to be about 7% because of a partial lack of knowledge about their properties, and therefore, of construction certifications. This work was intended to close a knowledge gap concerning emissions during pyrolysis, smoldering, and combustion of commercial insulating materials made from wood, cellulose, meadow grass, hemp, jute, cork, and seaweed as well as polystyrene for comparison reasons. Laboratory‐scale experiments were conducted and the measurement of thermal decomposition products was done with gas chromatography combined with mass spectrometry (GC/MS). It was realized that almost all the products could be assigned to the following eight substance classes: carbohydrates, aldehydes/ketones, carbonic acids/esters, substituted phenols, furans, aliphatic hydrocarbons, substituted benzenes, and polycyclic aromatic hydrocarbons. Substance spectra were generated that showed certain conformities, especially between the insulating materials made from wood, cellulose, and meadow grass as well as hemp and jute. Comparisons of the sum of peak areas in the GC/MS‐chromatograms provided indications of the relative extent of thermal decomposition product emissions. Calculations according to (∑peak areas renewable material )/(∑peak areas polystyrene ) revealed factors between 0.18 (wood, cork) and 0.028 (meadow grass). In the thermal emissions, defined hazardous substances or substance groups were frequently measured. These were included in a toxicity evaluation by which, inter alia, advantages of the natural products compared to polystyrene could be demonstrated.

Type of Medium: Online Resource

ISSN: 0308-0501 , 1099-1018

URL: Issue

URL: Article

DOI: 10.1002/fam.v47.1

DOI: 10.1002/fam.3064

Language: English

Publisher: Wiley

Publication Date: 2023

detail.hit.zdb_id: 2002816-7

In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 3383-3383

Abstract: Background. The depth of Hypogammaglobulinemia has been related to adverse prognosis in myeloma for decades, but most importantly, it has been suggested that its recovery following treatment was associated with good outcome and prolonged survival. However, none of the traditional techniques has allowed a precise measurement of isotype-matched (i.e. concentrations of IgGκ in an IgGλ myeloma patient) hypogammaglobulinemia. Recently, a new test quantifying paired clonal and non-clonal immunoglobulins (heavy/light chains HLC i.e. IgGκ/IgGλ) in serum was developed. Here we aim to assess the new HLC assays as tools to measure Hypogammaglobulinemia, and potentially replace traditional techniques for the monitoring of patients with myeloma. Materials and methods. 107 (59 IgGκ, 29 IgGλ, 12 IgAκ, 7 IgAλ) myeloma patients treated with pomalidomide and dexamethasone in two IFM studies (IFM 2009-02 in end-stage RRMM, and IFM 2010-02 in del17p and t(4;14) RRMM ) were included. The criteria for selection were that patients had measurable intact immunoglobulin myeloma according to IMWG criteria (M spike ≥10g/L), using serum and/or urine protein electrophoresis, with exclusion of patients solely measurable on UPEP and sFLC. All sera were collected centrally before initiation of treatment and sequentially every cycle until progression. Hevylite® (HLC) was measured in the biology laboratory of CHRU of Lille (France). For each patient we have measured the clonal isotype HLC level, and the corresponding non-clonal paired isotype HLC level, e.g. for IgAκ myeloma, the IgAλ non-clonal paired isotype. (Normal ranges: IgGκ 3.84-12.07, IgGλ 1.91-6.74 and IgGκ/IgGλ 1.12-3.21; IgAκ 0.57-2.08, IgAλ 0.44-2.04 and IgAκ/IgAλ 0.78-1.94 g/L). Results. Overall, 98 (92%) patients had an abnormal suppressed uninvolved HLC level at baseline with suppression being more common in IgG than IgA patients (95% v 73%, p 〈 0.001), and 94 (87%) at the time the greatest response was reached (IgG 90% 〉 IgA 77%), meaning that the vast majority of patients had not recovered from hypogammaglobulinemia at the time of best response. The median uninvolved IgG and IgA HLC concentrations at baseline were 0.62 and 0.2 g/L respectively (range: 05-6.9; 0.01-5.6). At best, response levels reached were 0.53 and 0.24g/L respectively (0.01-5.6; 0.01-7.4). Interestingly, more patients had recovered in the IFM 2009-02 study compared to the IFM2010-02 study, essentially different in the number of prior lines of therapy (3 and 9, respectively). We then sought to understand the relationship with response to therapy. We noted that very few patients’ hypogammaglobulinemia levels normalized completely, nor did their uninvolved paired isotype HLC levels normalize. However, we found that 55% of responders (IMWG) had improved levels (by at least 20%) of the uninvolved paired isotype HLC compared to 18.5% of the non-responders (p=0.001). Similarly, an improvement of at least 50% in the levels of uninvolved paired isotype HLC was achieved by 35% of responders compared to 13% of non-responders, respectively (p=0.013); an improvement of 75% was reached by 22.5% of responders and 7.4% of non-responders (p=0.028). This data strongly correlated to the depth of response, since, for example, 75% of patients in VGPR or better had improved levels of uninvolved paired isotype HLC by 50% at the time of greatest response, compared to 31% for PR and 13% for SD (p=0.005). Similar correlations were seen for 20% (p 〈 0.0001) and 75% (p=0.16) recoveries. Conclusion. The mechanism of immunosuppression in myeloma patients is poorly understood. Here we have shown for the first time that isotype-matched hypogammaglobulinemia correlates to depth of response. Hypogammaglobulinemia is important to assess not only because of its greater risk of infectious complications, often severe in myeloma, but also as it plays a predictive role in occurrence of response and more importantly depth of response. Future studies are needed to unravel the relationship between debulking of tumor cells and correction of hypogammaglobulinemia; in other words, is repopulating of the marrow with normal B cells associated to better outcome, and how does this affect the homeostasis of the bone marrow in its ability to support tumour cells. Disclosures Stoppa: Celgene Jansen: Honoraria. Marit:Celgene, Janssen: Congress expenses Other.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood.V124.21.3383.3383

Language: English

Publisher: American Society of Hematology

Publication Date: 2014

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 118, No. 22 ( 2011-11-24), p. 5752-5758

Abstract: The Intergroupe Francophone du Myelome conducted a randomized trial to compare bortezomib-dexamethasone (VD) as induction before high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to a combination consisting of reduced doses of bortezomib and thalidomide plus dexamethasone (vtD) in patients with multiple myeloma. Overall, a total of 199 patients were centrally randomly assigned to receive VD or vtD. After 4 cycles, the complete response (CR) rate was the same in both groups (13% in the vtD arm, 12% in the VD arm, P = .74). However, the CR plus very good partial response (VGPR) rate was significantly higher in the vtD arm (49% vs 36%, P = .05). After ASCT, the CR plus VGPR rate was significantly higher in the vtD arm (74% vs 58%, P = .02). The reduced doses of bortezomib and thalidomide translated into a reduced incidence of peripheral neuropathy (PN): grade ≥ 2 PN were reported in 34% in the VD arm versus 14% in the vtD arm (P = .001). vtD, including reduced doses of bortezomib and thalidomide, yields higher VGPR rates compared with VD and can be considered a new effective triplet combination before HDT/ASCT. This study was registered with www.clinicaltrials.gov as #NCT00910897 and EudraCT as #2007-005204-40.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2011-05-355081

Language: English

Publisher: American Society of Hematology

Publication Date: 2011

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 121, No. 11 ( 2013-03-14), p. 1968-1975

Abstract: Combination of pomalidomide with dexamethasone is highly active and can salvage end stage myeloma refractory to lenalidomide and bortezomib. Current data suggest pomalidomide 4 mg/day on days 1 to 21 per 28-days cycle with dexmethasone should be studied in future phase 3 trials.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2012-09-452375

Language: English

Publisher: American Society of Hematology

Publication Date: 2013

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 120, No. 21 ( 2012-11-16), p. 196-196

Abstract: Abstract 196 Until recent data, MM concept implies that all clones are linearly related to each other and homogenous in their mutational landscape. However, studies are now contradicting this model and reveal a more complex clonal architecture of Darwinian-like somatic evolution, where tumor progression proceeds in a branching rather than in a linear manner, leading to substantial clonal diversity and coexistence of wide genetic heterogeneity. By use of serial genomic analysis at different points during the disease course of MM patients, Keats et al. found the existence of 3 temporal tumor types, which can either be genetically stable, linearly evolving, or heterogeneous clonal mixtures with shifting predominant clones. In order to confirm these data we study on a large cohort of MM patients the emergence or disappearence by FISH analysis of t(4;14) and t(11;14) between diagnosis and relapse. We selected 444 patients from the IFM cell collection for whom we had a FISH analysis at diagnosis and relapse. Among them, 342 were evaluable for proceeding to FISH analysis. Upon receipt, bone marrow plasma cells were sorted using nanobeads and an anti-CD138 antibody (RoboSep, Stem Cell Technologies). After immuno-magnetic sorting, the plasma cell suspension purity was verified, and only samples with at least 90% of plasma cells were kept. Cells were then fixed in Carnoy's fixative. To test plasma cells for the t(4;14) and t(11;14), we did use specific IGH-FGFR3 and IGH-CCND1 fusion probes (Abbott Molecular). Hybridizations were performed according to the manufacturer's instructions. For analysis, at least 100 plasma cells with correct signals were scored using a Zeiss epifluorescence microscope. Our population baseline data presents usual characteristics: median age at diagnosis was 57 years (36y to 82y), diagnosis was made between 18/05/2000 and 19/08/2008. Relapse occurred between 11/08/2000 and 04/02/2009, with a median PFS of 26.6 months. The t(4;14) was present at diagnosis in 16.7% of the patients (38/232), and 11% (36/322) at relapse; Chi2 test did not find statistical difference between incidence at diagnosis and relapse (p=0.12). The t(11;14) was present in 24.6% of patients at diagnosis (48/195) but only 10.7% (20/187) at relapse (p=0.002). The purpose of our study was to explore clonal evolution during myeloma course. The t(4;14) translocation appeared (negative at diagnosis and positive at relapse) in 13 patients (n=218; 5.96%). On the contrary, t(4;14) disappeared in 11 cases (5.04%, n=218). In the same way, t(11;14) appeared for only 2 patients (1.42%, n=141) and disappeared in six cases (4.25%, n=141). Interestingly, we did not see switch between emergence and disappearance of the two translocations; no patient changed his cytogenetic status for one translocation to the other one. This phenomenon represents an important percentage of patients: for t(4;14), 11% of patients changed their status and 5.67% for t(11;14). Our data are in link with a study by Keats et al. who identified an evolution of aCGH data on a cohort of 28 patients showing changes over time for all their patients. Even if our data did not identify one of the three temporal tumor types described by Keats, the diversity of our findings (gain or loss of t(11;14) or t(4;14) between diagnosis and relapse) is an illustration on a large cohort of the clonal diversity and evolution of MM. Conclusion: this study describes for the first time on a large cohort of patients an aspect of subclonal evolution of MM. We identified a change of cytogenetic status for 11% of t(4–14) and 5,67% of t(11–14). These data illustrate the subclonal evolution of MM and underline the importance to perform novel cytogenetic analysis during disease course because treatment may be influenced by clonal expansion. Disclosures: Hulin: celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; janssen: Membership on an entity's Board of Directors or advisory committees. Kolb:janssen: Honoraria; celgene: Honoraria. Facon:onyx: Membership on an entity's Board of Directors or advisory committees; celgene: Membership on an entity's Board of Directors or advisory committees; janssen: Membership on an entity's Board of Directors or advisory committees; millenium: Membership on an entity's Board of Directors or advisory committees. Attal:celgene: Membership on an entity's Board of Directors or advisory committees; janssen: Membership on an entity's Board of Directors or advisory committees.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood.V120.21.196.196

Language: English

Publisher: American Society of Hematology

Publication Date: 2012

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 126, No. 23 ( 2015-12-03), p. 393-393

Abstract: Background Induction therapy followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with symptomatic multiple myeloma less than 66 years old. The quality of response to the induction treatment is an important prognostic factor and is predictive of progression free survival (PFS) following ASCT. The triplet combinations bortezomib-thalidomide-dexamethasone (VTD) and bortezomib-cyclophosphamide-dexamethasone (VCD) have demonstrated high response rates in prospective phase 2 and phase 3 clinical trials, they are 2 of the most commonly used induction regimens prior to ASCT, and are both recommended in the International guidelines. To date, no comparative data from prospective randomized trials of the safety and efficacy of VTD vs VCD are available. This provided the rationale for the phase 3 investigation of VTD vs VCD prior to ASCT in patients with de novo MM in this randomized multicenter study (NCT01564537). Methods Patients with de novo symptomatic MM less than 66 years old were prospectively randomized to receive either 4 cycles of VTD (arm A) or 4 cycles of VCD (arm B) followed by ASCT. The VTD regimen consisted of four 21-day cycles of bortezomib 1.3 mg/m²/d, subcutaneously (SC) D1, 4, 8 and 11, Dexamethasone 40 mg/d, PO D1 to 4, D9 to 12 and Thalidomide 100 mg/d, PO D1 to D21. The VCD regimen consisted of four 21-day cycles of bortezomib 1.3 mg/m²/d, SC D1, 4, 8 and 11, Dexamethasone 40 mg/d, PO D1 to 4, D9 to 12 and Cyclophosphamide 500 mg/m²/d, PO D1, 8, 15. Patients were stratified according to ISS (1-2 versus 3) and cytogenetics (high-risk defined by 17p deletion and t(4;14) versus other).The primary endpoint was very good partial response (VGPR) rate following 4 cycles. Response was assessed in a central lab according to the IMWG criteria. Assuming a VGPR rate of 60% in the VTD arm versus 45% in the VCD arm (15% difference), the possibility to detect a statistically significant difference required the enrolment of 340 patients overall (170 per arm). Adverse events were graded using the NCI CTCAE catalogue, version 4.0. Results From 11/2013 to 02/2015, 358 patients were enrolled into the study. 18 were screening failures, and 170 were randomized each to arm A (VTD) and arm B (VCD). The median age was 60 years (range, 26-65), 62% of the patients were male, and overall, the patient characteristics were well-balanced across the 2 arms of the study. The median number of induction cycles administered in both arms was 4 (1-4). On an intent-to-treat basis, the overall response rate ( 〉 partial response [PR]) was 92.3% in arm A, including a 10.7% complete response (CR) rate and a VGPR rate of 66.7%, while in arm B the overall response rate was 84%, with a 9.5% CR and a 56.2% VGPR rate. VGPR and PR rates were significantly higher in the VTD arm with p-values of 0.04 and 0.02, respectively. Seven patients died during induction therapy (2%), 3 in arm A from infections (2) and pulmonary embolism (1), and 4 in arm B from progression to extramedullary myeloma (2) and infections (2). Grades 3 / 4 peripheral neuropathy occurred in 4% and 2.2% in Arm A and B, respectively. Grade 3/4 neutropenia was seen in 11.9% vs 22.5% in Arm A and B, respectively. Conclusion This trial is the first prospective randomized comparison of 4 cycles of VTD versus 4 cycles of VCD administered as induction therapy prior to ASCT. VTD was shown to be significantly superior to VCD in terms of VGPR and PR rates. Neuropathy rates low in both arms, while neutropenia was more frequent with VCD. Disclosures Moreau: Millennium: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees. Hulin:Celgene Corporation: Honoraria; Janssen: Honoraria; Bristol Myers Squibb: Honoraria; Amgen: Honoraria. MACRO:celgene: Membership on an entity's Board of Directors or advisory committees; jansen: Membership on an entity's Board of Directors or advisory committees; millenium: Membership on an entity's Board of Directors or advisory committees. Garderet:Bristol-Myers Squibb: Consultancy. Stoppa:Celgene: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Facon:Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Millenium: Membership on an entity's Board of Directors or advisory committees; Onyx: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Pierre Fabre: Membership on an entity's Board of Directors or advisory committees. Laribi:Hospira SAS: Research Funding. Avet-Loiseau:jansen: Membership on an entity's Board of Directors or advisory committees; onyx: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; millenium: Membership on an entity's Board of Directors or advisory committees; millenium: Membership on an entity's Board of Directors or advisory committees; celgene: Membership on an entity's Board of Directors or advisory committees; jansen: Membership on an entity's Board of Directors or advisory committees; onyx: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees. Attal:jansen: Honoraria; celgene: Membership on an entity's Board of Directors or advisory committees.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood.V126.23.393.393

Language: English

Publisher: American Society of Hematology

Publication Date: 2015

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 122, No. 21 ( 2013-11-15), p. 689-689

Abstract: Multiple myeloma with del(17p) and/or t(4;14) are characterized with short survival related to early relapse rate (median TTP 〈 4 months) and rapid development of mechanisms of resistance to multiple agents. Furthermore, RRMM to IMiDs® imunomodulatory agent and proteasome inhibitors (bortezomib) also display a shortened median survival of approximately 9 months. We and others have previously showed that pomalidomide plus low-dose dexamethasone has produced 30% to 40% response rate (ORR, PR and greater) with prolonged duration of response (DOR) and median time to progression (TTP) in RRMM who have progressed after multiple treatment options. However, the median TTP was much shorter 〈 4 months for patients with del17p and/or t(4;14) who have been previously exposed to a median of 5- 6 lines of therapies in those studies. We have designed a phase 2 multicenter, open-label study aimed to determine the efficacy and safety profile of pomalidomide in RRMM patients with del(17p) and/or t(4;14). Method This study enrolled patients with progressive RRMM that were relapsing but not necessarily refractory to lenalidomide (minimum two cycles). Del(17p) and/or t(4;14) was identified centrally by Pr. Avet-Loiseau using FISH on bone marrow plasma cells. The response was evaluated centrally in Lille according to IMWG criteria. The primary objective was to evaluate TTP using pomalidomide plus low-dose dexamethasone in RRMM with del(17p) and/or t(4;14). Pomalidomide was given orally at 4 mg daily on days 1–21 of each 28-days and dexamethasone orally at 40 mg daily on days 1, 8, 15 and 22 of each cycle. Venous thrombotic events (VTE) prophylaxis was mandatory. The primary analysis was conducted on the ITT population. An interim analysis is reported. Results 50 patients (gender ratio 1.5) were enrolled, the median age was 59 yrs (range, 30-80). The median time from diagnosis to enrolment was 3 years (IQ 2-4), 40% had ISS 3, and 60% high beta2m. All patients had loss of 17p (46%) and/or t(4;14) (64%). At entry into the trial, 30% had Hb 〈 10 g/dL, 12% platelet count 〈 100 G/L and 4% neutrophils 〈 1 G/L, 6% had circulating plasma cells and 10% presence of clinically plasmacytomas. The median number of prior lines of therapy was 3 (1-10). All patients had prior exposure to lenalidomide with 84% refractory, 96% had received a proteasome inhibitor with 54% that became refractory; 90% had got an alkylating agent, with 36% became refractory; 76% had an autotransplant and 2% an allotransplant. Overall, 76% were refractory to the last line of therapy prior to study entry. The overall response rate (ORR) was 20% (27% in del17p and 16% in t(4;14)), including 6% 〉 VGPR, and 54% had stable disease. The median duration of response was not reached, but the 6-months event-free survival (EFS) was 54%. With a median follow-up of 5 months (IQ 3-11), 66% have stopped treatment including 76% due to progression of MM, and 38% had died. The median OS for the cohort as a whole is 12 months (CI95% 5;nr), with a 8-months event-free survival rate of 59%. Interestingly, del(17p) patients benefited more from pomalidomide plus low-dose dexamethasone as median OS was not reached, with 63% 8-months OS, while 9 months (4.5;16) for t(4;14). The median TTP for the cohort as a whole is approaching 3 months (2-5), nonetheless longer for del17p, 8 months (3;nr) versus 3 months (2;4) for t(4;14). We then concentrated on RRMM with more than 2 cycles, and found a similar profile with a clear cut benefit for del17p as compared to t(4;14) treated with pomalidomide plus low-dose dexamethasone. Toxicity was manageable in these fragile RRMM patients with 40% of serious adverse events (SAEs) reported related to the studied treatment, 13% of which led to death and 21% to permanent drug discontinuation. An other 48% led to drug dose reduction. No occurrence or worsening of neuropathy was reported, and only 1 pulmonary embolism was noted. Conclusion Pomalidomide plus low dose dexamethasone is active and well tolerated in this RRMM population characterized with high and rapid development of a refractoriness state, particularly with del(17p). This study provides further evidence that IMiD® compound, including pomalidomide is active in patients with adverse FISH cytogenetic and that ongoing triplet-based combination should demonstrate improved response rates and survival in future studies. Updated results will be presented at ASH2013. Disclosures: Leleu: JANSSEN: Honoraria; CELGENE: Honoraria. Off Label Use: Pomalidomide. Karlin:Janssen: Honoraria; Celgene: Export board committee Other, Honoraria. Roussel:JANSSEN: Honoraria; CELGENE: Honoraria. Moreau:JANSSEN: Honoraria, Speakers Bureau; CELGENE: Honoraria, Speakers Bureau. Attal:JANSSEN: Honoraria, Speakers Bureau; CELGENE: Honoraria, Speakers Bureau. Avet-Loiseau:JANSSEN: Honoraria, Speakers Bureau; CELGENE: Honoraria, Speakers Bureau. Facon:JANSSEN: Honoraria, Speakers Bureau; CELGENE: Honoraria, Speakers Bureau.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood.V122.21.689.689

Language: English

Publisher: American Society of Hematology

Publication Date: 2013

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Sensors and Actuators B: Chemical, Elsevier BV, Vol. 205 ( 2014-12), p. 39-49

Type of Medium: Online Resource

ISSN: 0925-4005

URL: Article

DOI: 10.1016/j.snb.2014.08.058

Language: English

Publisher: Elsevier BV

Publication Date: 2014

detail.hit.zdb_id: 1500731-5

detail.hit.zdb_id: 1021505-0

In: International Journal of Biological Macromolecules, Elsevier BV, Vol. 59 ( 2013-08), p. 111-118

Type of Medium: Online Resource

ISSN: 0141-8130

URL: Article

DOI: 10.1016/j.ijbiomac.2013.04.028

Language: English

Publisher: Elsevier BV

Publication Date: 2013

detail.hit.zdb_id: 1483284-7

SSG: 12